$CVS
CVS Health Corp Stock $cvs

$cvs Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000006480323000016 Filed on May 03, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$88.92B	$85.28B
YoY Change	10.27%	11.0%
Cost Of Revenue	$53.54B	$51.46B
YoY Change	8.61%	13.07%
Gross Profit	$35.39B	$33.82B
YoY Change	12.89%	8.0%
Gross Profit Margin	39.79%	39.66%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$1.001B
YoY Change		-5.12%
% of Gross Profit		2.96%
Operating Expenses	$31.66B	$30.03B
YoY Change	245.16%	204.05%
Operating Profit	$3.730B	$3.446B
YoY Change	-18.36%	-1.26%
Interest Expense	-$686.0M	$589.0M
YoY Change	-217.67%	0.51%
% of Operating Profit	-18.39%	17.09%
Other Income/Expense, Net	$22.00M	$22.00M
YoY Change	-48.84%	-47.62%
Pretax Income	$2.570B	$2.879B
YoY Change	-36.21%	-2.27%
Income Tax	$656.0M	$737.0M
% Of Pretax Income	25.53%	25.6%
Net Earnings	$1.901B	$2.136B
YoY Change	-35.58%	-7.61%
Net Earnings / Revenue	2.14%	2.5%
Basic Earnings Per Share	$1.48	$1.66
Diluted Earnings Per Share	$1.48	$1.65
COMMON SHARES
Basic Shares Outstanding	1.282B shares	1.284B shares
Diluted Shares Outstanding	1.287B shares	1.291B shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.89B	$17.72B
YoY Change	12.63%	56.23%
Cash & Equivalents	$13.81B	$14.62B
Short-Term Investments	$3.080B	$3.102B
Other Short-Term Assets	$4.032B	$3.767B
YoY Change	58.68%	-31.88%
Inventory	$17.29B	$18.26B
Prepaid Expenses
Receivables	$9.949B	$28.33B
Other Receivables	$19.60B	$2.320B
Total Short-Term Assets	$67.76B	$68.71B
YoY Change	9.03%	11.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$30.70B	$12.87B
YoY Change	140.55%	0.22%
Goodwill	$91.26B	$84.06B
YoY Change	16.17%	6.32%
Intangibles	$30.12B	$26.37B
YoY Change	7.05%	-7.62%
Long-Term Investments	$22.11B	$21.61B
YoY Change	4.69%	-4.35%
Other Assets	$8.119B	$4.824B
YoY Change	67.33%	-1.09%
Total Long-Term Assets	$182.3B	$170.6B
YoY Change	8.43%	-0.45%
TOTAL ASSETS
Total Short-Term Assets	$67.76B	$68.71B
Total Long-Term Assets	$182.3B	$170.6B
Total Assets	$250.1B	$239.3B
YoY Change	8.59%	2.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$45.78B	$43.47B
YoY Change	8.92%	4.57%
Accrued Expenses	$24.38B	$21.52B
YoY Change	37.5%	29.46%
Deferred Revenue	$161.0M	$136.0M
YoY Change	101.25%	70.0%
Short-Term Debt	$1.000B	$0.00
YoY Change
Long-Term Debt Due	$1.402B	$1.778B
YoY Change	-65.12%	-57.84%
Total Short-Term Liabilities	$79.21B	$75.05B
YoY Change	15.7%	7.56%
LONG-TERM LIABILITIES
Long-Term Debt	$61.42B	$56.45B
YoY Change	20.91%	8.43%
Other Long-Term Liabilities	$31.86B	$6.671B
YoY Change	1388.6%	197.55%
Total Long-Term Liabilities	$93.28B	$6.671B
YoY Change	4258.64%	197.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$79.21B	$75.05B
Total Long-Term Liabilities	$93.28B	$6.671B
Total Liabilities	$177.3B	$167.8B
YoY Change	14.58%	5.68%
SHAREHOLDERS EQUITY
Retained Earnings	$58.87B	$57.75B
YoY Change	0.27%	2.24%
Common Stock	$18.00M	$18.00M
YoY Change	0.0%	5.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$33.80B
YoY Change		12.13%
Treasury Stock Shares		480.0M shares
Shareholders Equity	$72.73B	$71.38B
YoY Change
Total Liabilities & Shareholders Equity	$250.1B	$239.3B
YoY Change	8.59%	2.77%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	$1.901B	$2.136B
YoY Change	-35.58%	-7.61%
Depreciation, Depletion And Amortization		$1.001B
YoY Change		-5.12%
Cash From Operating Activities	$5.908B	$7.438B
YoY Change	8.54%	108.76%
INVESTING ACTIVITIES
Capital Expenditures	$591.0M	$984.0M
YoY Change	-256.76%	-6.37%
Acquisitions		$7.094B
YoY Change		101242.86%
Other Investing Activities	-$9.771B	-$31.00M
YoY Change	457.39%	-200.0%
Cash From Investing Activities	-$10.36B	-$8.514B
YoY Change	386.48%	327.2%
FINANCING ACTIVITIES
Cash Dividend Paid		$779.0M
YoY Change		7.89%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$362.0M
YoY Change		2485.71%
Cash From Financing Activities	3.626B	$2.726B
YoY Change	-247.34%	-202.87%
NET CHANGE
Cash From Operating Activities	5.908B	$7.438B
Cash From Investing Activities	-10.36B	-$8.514B
Cash From Financing Activities	3.626B	$2.726B
Net Change In Cash	-828.0M	$1.650B
YoY Change	-197.18%	-252.78%
FREE CASH FLOW
Cash From Operating Activities	$5.908B	$7.438B
Capital Expenditures	$591.0M	$984.0M
Free Cash Flow	$5.317B	$6.454B
YoY Change	-8.64%	156.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000064803
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations
CY2023Q1	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations
CY2023Q1	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201812Member
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-01011
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CVS HEALTH CORPORATION
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	05-0494040
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	One CVS Drive,
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Woonsocket,
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	RI
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02895
CY2023Q1	dei	City Area Code CityAreaCode	(401)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	765-1500
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	CVS
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1282025283	shares
CY2023Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	24352000000	usd
CY2022Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	21631000000	usd
CY2023Q1	us-gaap	Net Investment Income NetInvestmentIncome	334000000	usd
CY2022Q1	us-gaap	Net Investment Income NetInvestmentIncome	168000000	usd
CY2023Q1	us-gaap	Revenues Revenues	85278000000	usd
CY2022Q1	us-gaap	Revenues Revenues	76826000000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	51455000000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	45509000000	usd
CY2023Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	20448000000	usd
CY2022Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	17923000000	usd
CY2023Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2022Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-484000000	usd
CY2023Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	349000000	usd
CY2022Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	41000000	usd
CY2023Q1	cvs	Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement	9580000000	usd
CY2022Q1	cvs	Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement	9324000000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	81832000000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	73281000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3446000000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3545000000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	589000000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	586000000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22000000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	42000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2879000000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3001000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	737000000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	646000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2142000000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	2355000000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	6000000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	2136000000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	2354000000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.66
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.79
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.65
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.77
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1283000000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1312000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1291000000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1328000000	shares
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.605
CY2022Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.55
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2142000000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	2355000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	470000000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1132000000	usd
CY2023Q1	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	-74000000	usd
CY2022Q1	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	369000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-6000000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-3000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	389000000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-763000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	2531000000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1592000000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	6000000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2525000000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1591000000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14618000000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12945000000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	3102000000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	2778000000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28331000000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27276000000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	18263000000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	19090000000	usd
CY2023Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	625000000	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	908000000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	3767000000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2636000000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	68706000000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	65633000000	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	21612000000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	21096000000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12872000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12873000000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17660000000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17872000000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	84057000000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	78150000000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26368000000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24803000000	usd
CY2023Q1	us-gaap	Separate Account Assets SeparateAccountAssets	3231000000	usd
CY2022Q4	us-gaap	Separate Account Assets SeparateAccountAssets	3228000000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4824000000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4620000000	usd
CY2023Q1	us-gaap	Assets Assets	239330000000	usd
CY2022Q4	us-gaap	Assets Assets	228275000000	usd
CY2023Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	12527000000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	14838000000	usd
CY2023Q1	cvs	Pharmacy Claims And Discounts Payable Current PharmacyClaimsAndDiscountsPayableCurrent	20047000000	usd
CY2022Q4	cvs	Pharmacy Claims And Discounts Payable Current PharmacyClaimsAndDiscountsPayableCurrent	19423000000	usd
CY2023Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	10895000000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	10142000000	usd
CY2023Q1	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	1426000000	usd
CY2022Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	1500000000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21515000000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18745000000	usd
CY2023Q1	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	4974000000	usd
CY2022Q4	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1089000000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1679000000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1678000000	usd
CY2023Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1778000000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1778000000	usd
CY2023Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	213000000	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	228000000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	75054000000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	69421000000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16571000000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16800000000	usd
CY2023Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	56450000000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	50476000000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4095000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4016000000	usd
CY2023Q1	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3231000000	usd
CY2022Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3228000000	usd
CY2023Q1	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	5678000000	usd
CY2022Q4	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	5835000000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6671000000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6730000000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	167750000000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	156506000000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1759000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1279000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1758000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1300000000	shares
CY2023Q1	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	48306000000	usd
CY2022Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	48193000000	usd
CY2023Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	480000000	shares
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	458000000	shares
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	33802000000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	31858000000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	57753000000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	56398000000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-875000000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1264000000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	71382000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	71469000000	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	198000000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	300000000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71580000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71769000000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	239330000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	228275000000	usd
CY2023Q1	us-gaap	Proceeds From Customers ProceedsFromCustomers	87798000000	usd
CY2022Q1	us-gaap	Proceeds From Customers ProceedsFromCustomers	74192000000	usd
CY2023Q1	cvs	Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies	50223000000	usd
CY2022Q1	cvs	Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies	44365000000	usd
CY2023Q1	cvs	Payments For Insurance Benefits PaymentsForInsuranceBenefits	19757000000	usd
CY2022Q1	cvs	Payments For Insurance Benefits PaymentsForInsuranceBenefits	16616000000	usd
CY2023Q1	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	9958000000	usd
CY2022Q1	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	8969000000	usd
CY2023Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	426000000	usd
CY2022Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	199000000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	773000000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	782000000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	75000000	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	96000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7438000000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3563000000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1891000000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2570000000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2358000000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3474000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	984000000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1051000000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	7094000000	usd
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	7000000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-31000000	usd
CY2022Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	31000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8514000000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1993000000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5951000000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	362000000	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	14000000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2018000000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2000000000	usd
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	779000000	usd
CY2022Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	722000000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	96000000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	297000000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	34000000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	62000000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-128000000	usd
CY2022Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-149000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2726000000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2650000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1650000000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1080000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13305000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12691000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14955000000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11611000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2142000000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	2355000000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1001000000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1049000000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	103000000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	89000000	usd
CY2023Q1	cvs	Deferred Income Taxes And Other Noncash Items DeferredIncomeTaxesAndOtherNoncashItems	155000000	usd
CY2022Q1	cvs	Deferred Income Taxes And Other Noncash Items DeferredIncomeTaxesAndOtherNoncashItems	-175000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	751000000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1967000000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-828000000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	400000000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1255000000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	348000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1203000000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1974000000	usd
CY2023Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	4382000000	usd
CY2022Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	1430000000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2036000000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-444000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7438000000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3563000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71769000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2142000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	389000000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	122000000	usd
CY2023Q1	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	1962000000	usd
CY2023Q1	us-gaap	Dividends Common Stock DividendsCommonStock	781000000	usd
CY2023Q1	cvs	Noncontrolling Interest Other Period Increase Decrease NoncontrollingInterestOtherPeriodIncreaseDecrease	-99000000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71580000000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	75381000000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	2355000000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-763000000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	300000000	usd
CY2022Q1	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	1972000000	usd
CY2022Q1	us-gaap	Dividends Common Stock DividendsCommonStock	730000000	usd
CY2022Q1	cvs	Noncontrolling Interest Other Period Increase Decrease NoncontrollingInterestOtherPeriodIncreaseDecrease	3000000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	74034000000	usd
CY2022Q1	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2022Q4	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2021Q4	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2023Q1	cvs	Treasury Stock Shares Held In Trust TreasuryStockSharesHeldInTrust	1000000	shares
CY2023Q1	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2022Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2021Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2022Q1	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	18000000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18000000	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	17000000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17000000	usd
CY2023Q1	cvs	Number Of Pharmacy Plan Members NumberOfPharmacyPlanMembers	110000000	people
CY2023Q1	cvs	Number Of Patients Served Per Year NumberOfPatientsServedPerYear	1000000	patient
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div>
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14618000000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12945000000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	107000000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	144000000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	230000000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	216000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14955000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13305000000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	9229000000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8983000000	usd
CY2023Q1	cvs	Vendor And Manufacturer Receivables VendorAndManufacturerReceivables	13357000000	usd
CY2022Q4	cvs	Vendor And Manufacturer Receivables VendorAndManufacturerReceivables	12395000000	usd
CY2023Q1	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	3636000000	usd
CY2022Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	2676000000	usd
CY2023Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2320000000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3449000000	usd
CY2023Q1	cvs	Accounts Receivable After Allowance For Credit Loss Current Including Assets Held For Sale AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale	28542000000	usd
CY2022Q4	cvs	Accounts Receivable After Allowance For Credit Loss Current Including Assets Held For Sale AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale	27503000000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	324000000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	333000000	usd
CY2022Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1219000000	usd
CY2021Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	879000000	usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	135000000	usd
CY2022Q1	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	139000000	usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	64000000	usd
CY2022Q1	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	47000000	usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1290000000	usd
CY2022Q1	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	971000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000000	usd
CY2023Q1	us-gaap	Net Investment Income NetInvestmentIncome	334000000	usd
CY2023Q1	us-gaap	Revenues Revenues	85278000000	usd
CY2022Q1	us-gaap	Net Investment Income NetInvestmentIncome	168000000	usd
CY2022Q1	us-gaap	Revenues Revenues	76826000000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	9229000000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8983000000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	136000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	87000000	usd
CY2023Q1	cvs	Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance	82000000	usd
CY2022Q1	cvs	Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance	80000000	usd
CY2023Q1	cvs	Contractwith Customer Liability Redemptionand Breakage ContractwithCustomerLiabilityRedemptionandBreakage	85000000	usd
CY2022Q1	cvs	Contractwith Customer Liability Redemptionand Breakage ContractwithCustomerLiabilityRedemptionandBreakage	87000000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination	68000000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination	0	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	136000000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	80000000	usd
CY2023Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	17000000	usd
CY2022Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	15000000	usd
CY2023Q1	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	19000000	usd
CY2022Q1	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	21000000	usd
CY2022Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	17923000000	usd
CY2022Q1	cvs	Operating Expenses Excluding Goodwill Impairments Loss On Assets Held For Sale And Loss On Litigation Settlement OperatingExpensesExcludingGoodwillImpairmentsLossOnAssetsHeldForSaleAndLossOnLitigationSettlement	9324000000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	73281000000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3545000000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3001000000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	646000000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	2355000000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	2354000000	usd
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.79
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.77
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2636000000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	65633000000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24803000000	usd
CY2022Q4	us-gaap	Assets Assets	228275000000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	10142000000	usd
CY2022Q4	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1089000000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	69421000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4016000000	usd
CY2022Q4	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	5835000000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6730000000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	156506000000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	56398000000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1264000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	71469000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71769000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	228275000000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	2355000000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1049000000	usd
CY2022Q1	cvs	Deferred Income Taxes And Other Noncash Items DeferredIncomeTaxesAndOtherNoncashItems	-175000000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	348000000	usd
CY2022Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	1430000000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-444000000	usd
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	6000000000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	3102000000	usd
CY2023Q1	cvs	Long Term Investments Including Assets Held For Sale LongTermInvestmentsIncludingAssetsHeldForSale	21612000000	usd
CY2023Q1	us-gaap	Investments Investments	24714000000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	2778000000	usd
CY2022Q4	cvs	Long Term Investments Including Assets Held For Sale LongTermInvestmentsIncludingAssetsHeldForSale	21113000000	usd
CY2022Q4	us-gaap	Investments Investments	23891000000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	22117000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	3000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	22114000000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	101000000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1393000000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	20822000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	22067000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	4000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	22063000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	57000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1840000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	20280000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	7374000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	288000000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	1412000000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1395000000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	6823000000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	6510000000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	4627000000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	4299000000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	4297000000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	3960000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	22114000000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	20822000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	4797	security
CY2022Q1	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	38000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	6231	security
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	9572000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1105000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	11028	security
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	16946000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1393000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	9500	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	14228000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1226000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	2784	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	4264000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	614000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	12284	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	18492000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1840000000	usd
CY2023Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear	1222000000	usd
CY2023Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss	18000000	usd
CY2023Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears	5363000000	usd
CY2023Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss	333000000	usd
CY2023Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears	3291000000	usd
CY2023Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss	358000000	usd
CY2023Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears	3032000000	usd
CY2023Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss	377000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	16946000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1393000000	usd
CY2022Q1	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	18000000	usd
CY2023Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	449000000	usd
CY2022Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	252000000	usd
CY2023Q1	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	10000000	usd
CY2022Q1	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	9000000	usd
CY2023Q1	cvs	Investment Income Excluding Capital Gains Or Losses InvestmentIncomeExcludingCapitalGainsOrLosses	439000000	usd
CY2022Q1	cvs	Investment Income Excluding Capital Gains Or Losses InvestmentIncomeExcludingCapitalGainsOrLosses	243000000	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-105000000	usd
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-75000000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	334000000	usd
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	168000000	usd
CY2023Q1	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	1000000	usd
CY2023Q1	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	24000000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1341000000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1911000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	3000000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	14000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	111000000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	35000000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	29000000	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	3000000	usd
CY2023Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the three months ended March 31, 2023 and 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,670 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,828 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,602 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,408 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,902 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Impact of discount rate on long-duration insurance reserves </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,895 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,105 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the difference between the current discount rate and the locked-in discount rate on long-duration insurance reserves which is recorded within accumulated other comprehensive loss on the unaudited condensed consolidated balance sheets. Refer to Note 1 ‘‘Significant Accounting Policies’’ for further information related to the adoption of the long-duration insurance contracts accounting standard. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total incurred health care costs for the three months ended March 31, 2023 and 2022 in the table above exclude $22 million and $21 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and $51 million and $61 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets. The incurred health care costs for the three months ended March 31, 2022 also exclude $13 million for a premium deficiency reserve related to the Company’s Medicaid products.</span></div>(3)As a result of the divestiture of the international health care business domiciled in Thailand (“Thailand business”), the net assets associated with this business were accounted for as assets held for sale and the associated health care costs payable balance was included in accrued expenses on the unaudited condensed consolidated balance sheet at March 31, 2022.
CY2023Q1	us-gaap	Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet	8000000000	usd
CY2022Q4	us-gaap	Policyholder Funds PolicyholderFunds	345000000	usd
CY2021Q4	us-gaap	Policyholder Funds PolicyholderFunds	522000000	usd
CY2023Q1	cvs	Policyholder Account Balance Deposits Received PolicyholderAccountBalanceDepositsReceived	4000000	usd
CY2022Q1	cvs	Policyholder Account Balance Deposits Received PolicyholderAccountBalanceDepositsReceived	2000000	usd
CY2023Q1	us-gaap	Policyholder Account Balance Surrender And Withdrawal PolicyholderAccountBalanceSurrenderAndWithdrawal	7000000	usd
CY2022Q1	us-gaap	Policyholder Account Balance Surrender And Withdrawal PolicyholderAccountBalanceSurrenderAndWithdrawal	4000000	usd
CY2023Q1	us-gaap	Interest Credited To Policyholders Account Balances InterestCreditedToPolicyholdersAccountBalances	3000000	usd
CY2022Q1	us-gaap	Interest Credited To Policyholders Account Balances InterestCreditedToPolicyholdersAccountBalances	4000000	usd
CY2023Q1	cvs	Policyholder Account Balance Change In Net Unrealized Gains Losses PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses	21000000	usd
CY2022Q1	cvs	Policyholder Account Balance Change In Net Unrealized Gains Losses PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses	-72000000	usd
CY2023Q1	us-gaap	Policyholder Account Balance Increase Decrease From Other Change PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange	-9000000	usd
CY2022Q1	us-gaap	Policyholder Account Balance Increase Decrease From Other Change PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange	-4000000	usd
CY2023Q1	us-gaap	Policyholder Funds PolicyholderFunds	349000000	usd
CY2022Q1	us-gaap	Policyholder Funds PolicyholderFunds	444000000	usd
CY2023Q1	us-gaap	Policyholder Account Balance Weighted Average Crediting Rate PolicyholderAccountBalanceWeightedAverageCreditingRate	0.0455
CY2022Q1	us-gaap	Policyholder Account Balance Weighted Average Crediting Rate PolicyholderAccountBalanceWeightedAverageCreditingRate	0.0465
CY2023Q1	us-gaap	Policyholder Account Balance Net Amount At Risk PolicyholderAccountBalanceNetAmountAtRisk	0	usd
CY2022Q1	us-gaap	Policyholder Account Balance Net Amount At Risk PolicyholderAccountBalanceNetAmountAtRisk	0	usd
CY2023Q1	us-gaap	Cash Surrender Value Due Policyholders Amount CashSurrenderValueDuePolicyholdersAmount	332000000	usd
CY2022Q1	us-gaap	Cash Surrender Value Due Policyholders Amount CashSurrenderValueDuePolicyholdersAmount	342000000	usd
CY2022Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3228000000	usd
CY2021Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	5087000000	usd
CY2023Q1	us-gaap	Separate Account Liability Premium And Deposit SeparateAccountLiabilityPremiumAndDeposit	246000000	usd
CY2022Q1	us-gaap	Separate Account Liability Premium And Deposit SeparateAccountLiabilityPremiumAndDeposit	216000000	usd
CY2023Q1	us-gaap	Separate Account Liability Surrender And Withdrawal SeparateAccountLiabilitySurrenderAndWithdrawal	0	usd
CY2022Q1	us-gaap	Separate Account Liability Surrender And Withdrawal SeparateAccountLiabilitySurrenderAndWithdrawal	4000000	usd
CY2023Q1	us-gaap	Separate Account Liability Benefit Payment SeparateAccountLiabilityBenefitPayment	260000000	usd
CY2022Q1	us-gaap	Separate Account Liability Benefit Payment SeparateAccountLiabilityBenefitPayment	236000000	usd
CY2023Q1	us-gaap	Separate Account Liability Increase Decrease From Invested Performance SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance	23000000	usd
CY2022Q1	us-gaap	Separate Account Liability Increase Decrease From Invested Performance SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance	-393000000	usd
CY2023Q1	us-gaap	Transfer To From Policyholder Account Balance To From Separate Account TransferToFromPolicyholderAccountBalanceToFromSeparateAccount	0	usd
CY2022Q1	us-gaap	Transfer To From Policyholder Account Balance To From Separate Account TransferToFromPolicyholderAccountBalanceToFromSeparateAccount	5000000	usd
CY2023Q1	us-gaap	Separate Account Liability Increase Decrease From Other Change SeparateAccountLiabilityIncreaseDecreaseFromOtherChange	-6000000	usd
CY2022Q1	us-gaap	Separate Account Liability Increase Decrease From Other Change SeparateAccountLiabilityIncreaseDecreaseFromOtherChange	-5000000	usd
CY2023Q1	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3231000000	usd
CY2022Q1	us-gaap	Separate Accounts Liability SeparateAccountsLiability	4670000000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2023Q1	us-gaap	Separate Account Liability Cash Surrender Value Amount SeparateAccountLiabilityCashSurrenderValueAmount	2142000000	usd
CY2022Q1	us-gaap	Separate Account Liability Cash Surrender Value Amount SeparateAccountLiabilityCashSurrenderValueAmount	3204000000	usd
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	1483000000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1465000000	usd
CY2023Q1	cvs	Long Term Debt Gross And Lease Obligation LongTermDebtGrossAndLeaseObligation	58768000000	usd
CY2022Q4	cvs	Long Term Debt Gross And Lease Obligation LongTermDebtGrossAndLeaseObligation	52753000000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	198000000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	200000000	usd
CY2023Q1	cvs	Debt Instrument Unamortized Discountand Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet	735000000	usd
CY2022Q4	cvs	Debt Instrument Unamortized Discountand Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet	696000000	usd
CY2023Q1	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	58231000000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	52257000000	usd
CY2023Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1778000000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1778000000	usd
CY2023Q1	cvs	Long Term Debt And Lease Obligation Including Liabilities Held For Sale LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale	56453000000	usd
CY2022Q4	cvs	Long Term Debt And Lease Obligation Including Liabilities Held For Sale LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale	50479000000	usd
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	6000000000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.605
CY2022Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.55
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	389000000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-763000000	usd
CY2022Q1	us-gaap	Revenues Revenues	76826000000	usd
CY2022Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4607000000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2136000000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2354000000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1283000000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1312000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1291000000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1328000000	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.66
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.79
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.65
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.77
CY2023Q1	cvs	Guarantor Obligations Number Of Leases GuarantorObligationsNumberOfLeases	64	lease
CY2023Q1	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	84944000000	usd
CY2023Q1	us-gaap	Net Investment Income NetInvestmentIncome	334000000	usd
CY2023Q1	us-gaap	Revenues Revenues	85278000000	usd
CY2023Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4370000000	usd
CY2022Q1	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	76658000000	usd
CY2022Q1	us-gaap	Net Investment Income NetInvestmentIncome	168000000	usd
CY2022Q1	us-gaap	Revenues Revenues	76826000000	usd
CY2022Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4607000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3446000000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3545000000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	402000000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	462000000	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-105000000	usd
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-75000000	usd
CY2023Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	349000000	usd
CY2022Q1	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	41000000	usd
CY2023Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	43000000	usd
CY2022Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	0	usd
CY2023Q1	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	25000000	usd
CY2022Q1	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	0	usd
CY2023Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2022Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-484000000	usd
CY2023Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4370000000	usd
CY2022Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4607000000	usd

Files In Submission

Name	View Source	Status
0000064803-23-000016-index-headers.html	Edgar Link	pending
0000064803-23-000016-index.html	Edgar Link	pending
0000064803-23-000016.txt	Edgar Link	pending
0000064803-23-000016-xbrl.zip	Edgar Link	pending
a03312023ex101.htm	Edgar Link	pending
a03312023ex102.htm	Edgar Link	pending
a03312023ex103.htm	Edgar Link	pending
a03312023ex104.htm	Edgar Link	pending
a03312023ex105.htm	Edgar Link	pending
a03312023ex106.htm	Edgar Link	pending
a03312023ex107.htm	Edgar Link	pending
a03312023ex151.htm	Edgar Link	pending
a03312023ex311.htm	Edgar Link	pending
a03312023ex312.htm	Edgar Link	pending
a03312023ex321.htm	Edgar Link	pending
a03312023ex322.htm	Edgar Link	pending
cvs-20230331.htm	Edgar Link	pending
cvs-20230331.xsd	Edgar Link	pending
cvs-20230331_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
cvs-20230331_cal.xml	Edgar Link	unprocessable
cvs-20230331_lab.xml	Edgar Link	unprocessable
cvs-20230331_def.xml	Edgar Link	unprocessable
cvs-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cvs-20230331_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVS
CVS Health Corp Stock $cvs

2023 Q2 Form 10-Q Financial Statement

#000006480323000016 Filed on May 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS CVS Health Corp Stock $cvs

2023 Q2 Form 10-Q Financial Statement

#000006480323000016 Filed on May 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS
CVS Health Corp Stock $cvs